Entropy Technologies LP decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 60.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,233 shares of the biopharmaceutical company's stock after selling 284,653 shares during the period. Entropy Technologies LP's holdings in Pfizer were worth $4,744,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Pfizer by 7.7% during the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after buying an additional 4,167,222 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Pfizer by 3.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after buying an additional 1,333,740 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after buying an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after buying an additional 1,846,436 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
PFE has been the topic of a number of recent analyst reports. Redburn Atlantic cut their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Finally, Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $28.12.
Get Our Latest Report on PFE
Pfizer Stock Performance
Shares of NYSE:PFE traded up $0.03 on Monday, hitting $24.61. 38,065,234 shares of the company were exchanged, compared to its average volume of 46,565,748. The company's 50 day moving average price is $24.44 and its two-hundred day moving average price is $24.48. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $139.93 billion, a price-to-earnings ratio of 13.09, a PEG ratio of 0.88 and a beta of 0.52.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories

Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.